Raltegravir treatment response in an HIV-2 infected patient: A case report

AIDS

Volumn 22, Issue 9, 2008, Pages 1091-1092

  Garrett, Nigel ^a   Xu, Li ^b   Smit, Erasmus ^b   Ferns, Bridget ^c   El Gadi, Saleh ^a   Anderson, Jane ^a  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; RALTEGRAVIR; ZIDOVUDINE;

GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETTER; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT RESPONSE; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

ADULT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MALE; PYRROLIDINONES; VIRAL LOAD;

EID: 44449096529     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f9b165     Document Type: Letter

References (10)

1. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
2. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection. Results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
3. Hazuda DJ, Miller MD, Hguyen BY. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antivir Ther 2007; 12:S10.
4. McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, Chuk S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir Ther 2007; 12:S11.
5. Malet I, Delelis O, Calvez V. Biochemical characterizations of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518). Antivir Ther 2007; 12:S9.
6. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9:3-12.
7. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007; 51:604-610.
8. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK, et al. Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A 2002; 99:14410-14415.
9. Xu L, Anderson J, Ferns B, Cook P, Wildfire A, Workman J, et al. Genetic diversity of integrase sequences in antiretroviral treatment naïve and experienced HIV-2 patients. AIDS Res Hum Retroviruses (in press).
10. Roquebert B, Damond F, Peytavin G, et al. Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors: raltegravir and elvitegravir. 11th European AIDS Conference, 2007 Poster presentation. P7.8/01. 2007. 24-10-2007.